跳至主要内容
临床试验/RBR-9x6yxbv
RBR-9x6yxbv招募中不适用

Epidemiology and oral disease-modifying therapies for Multiple Sclerosis

niversidade Federal de Mato Grosso do Sul0 个研究点开始时间: 2021年12月29日最近更新:

试验速览

阶段
不适用
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18Y 至 0(—)

入选标准

  • Individuals over 18 years of age; of both sexes; diagnosed with Multiple Sclerosis represented by the G-35 code, which encompasses the group of diseases of the nervous system in the 10th edition of the International Statistical Classification of Diseases and Related Health Problems (ICD 10); assisted by the Specialized component of the Pharmaceutical Assistance of Mato Grosso do Sul; undergoing treatment, for at least three months, with one of the following oral administration medications: Teriflunomide 14mg, Dimethyl fumarate 240mg or Fingolimod 0.5mg; with at least one result of the Expanded Disability Status Scale (EDSS) prior to and one subsequent to the initiation of treatment with the oral medications described above

排除标准

  • Individuals with cognitive alterations that make it difficult to remember facts related to their illness; individuals with cognitive alterations that make it difficult to understand the research

研究者

发起方
niversidade Federal de Mato Grosso do Sul

相似试验